Holders — by stockHoldings — by fund
Avoro Capital Advisors LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001633313
$11.14B
disclosed book value
26
positions
13.5%
largest position share
Positions, as of 2026-06-30
top 26 of 26 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | UTHRUNITED THERAPEUTICS CORP | 2.8M | $1.51B | 13.5% |
| 2 | ASCENDIS PHARMA | 5.1M | $1.36B | 12.2% |
| 3 | KRYSKRYSTAL BIOTECH INC | 2.9M | $1.07B | 9.6% |
| 4 | MDGLMADRIGAL PHARMACEUTICALS INC | 1.8M | $984.4M | 8.8% |
| 5 | ARGXARGENX SE | 1.0M | $927.8M | 8.3% |
| 6 | ARWRARROWHEAD PHARMACEUTICALS INC | 11.4M | $925.6M | 8.3% |
| 7 | KYMRKYMERA THERAPEUTICS INC | 7.5M | $857.1M | 7.7% |
| 8 | RVMDREVOLUTION MEDICINES INC | 2.3M | $430.2M | 3.9% |
| 9 | CYTKCYTOKINETICS INC | 5.0M | $425.9M | 3.8% |
| 10 | CELCCELCUITY INC | 3.4M | $355.7M | 3.2% |
| 11 | GPCRSTRUCTURE THERAPEUTICS INC | 6.6M | $351.8M | 3.2% |
| 12 | XENEXENON PHARMACEUTICALS INC | 5.8M | $348.7M | 3.1% |
| 13 | DFTXDEFINIUM THERAPEUTICS INC | 7.2M | $338.2M | 3% |
| 14 | UNIQURE NV | 6.7M | $309.9M | 2.8% |
| 15 | VERAVERA THERAPEUTICS INC | 5.7M | $245.6M | 2.2% |
| 16 | TSHATAYSHA GENE THERAPIES INC | 23.9M | $162.7M | 1.5% |
| 17 | OCULOCULAR THERAPEUTIX INC | 12.5M | $123.1M | 1.1% |
| 18 | DAMORA THERAPEUTICS INC | 3.8M | $98.4M | 0.9% |
| 19 | COAGHEMAB THERAPEUTICS HLDGS INC | 1.9M | $70.7M | 0.6% |
| 20 | GH RESEARCH PLC | 1.8M | $48.4M | 0.4% |
| 21 | VRDNVIRIDIAN THERAPEUTICS INC | 2.5M | $45.9M | 0.4% |
| 22 | SEPNSEPTERNA INC | 1.3M | $44.8M | 0.4% |
| 23 | AVTXAVALO THERAPEUTICS | 2.3M | $43.1M | 0.4% |
| 24 | FTHFAETH THERAPEUTICS INC | 1.4M | $36.1M | 0.3% |
| 25 | WHWKWHITEHAWK THERAPEUTICS INC | 2.8M | $13.1M | 0.1% |
| 26 | LXEOLEXEO THERAPEUTICS INC | 1.5M | $6.9M | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.